GemPharmatech Co (SHSE:688046) ROCE %: 9.35% (As of Mar. 2026)


SHSE:688046 GemPharmatech Co Ltd SHSE:688046
95 GF Score
Price ¥25.77
GF Value ¥19.42
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is GemPharmatech Co ROCE %?

GemPharmatech Co SHSE:688046 +6.49% 95 ROCE % is 9.35% as of Mar. 2026. GuruFocus rates SHSE:688046 with a GF Score™ of 95/100 and a GF Value™ of ¥19.42 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GemPharmatech Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.35%.

GemPharmatech Co  (SHSE:688046) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GemPharmatech Co ROCE % Related Terms

GemPharmatech Co ROCE % Historical Data

* Premium members only.

The historical data trend for GemPharmatech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GemPharmatech Co ROCE % Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 18.05 12.00 7.72 5.60 7.53

GemPharmatech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.70 8.62 7.83 8.00 9.35
SHSE:688046
95GF Score
GemPharmatech Co Ltd SHSE:688046
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GemPharmatech Co ROCE % Calculation

GemPharmatech Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=171/( ( (2572.645 - 371.196) + (2865.067 - 527.144) )/ 2 )
=171/( (2201.449+2337.923)/ 2 )
=171/2269.686
=7.53 %

GemPharmatech Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=220.972/( ( (2865.067 - 527.144) + (2868.038 - 477.623) )/ 2 )
=220.972/( ( 2337.923 + 2390.415 )/ 2 )
=220.972/2364.169
=9.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.35% mean?
GemPharmatech Co (SHSE:688046) has a ROCE % of 9.35% as of Mar. 2026.
Is GemPharmatech Co's ROCE % too high?
GemPharmatech Co's current ROCE % is 9.35%. Overall, GemPharmatech Co has a GF Score™ of 95/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's ROCE % compare to VRTX and REGN?
GemPharmatech Co's ROCE % of 9.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. GemPharmatech Co's current ROCE % is 9.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.42, compared to a current price of ¥25.77 — trading 32.7% above its estimated fair value. The current ROCE % is 9.35%. GemPharmatech Co's overall GF Score™ is 95/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current ROCE % is 9.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?

Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued. The current stock price of ¥25.77 is trading 32.7% above its estimated GF Value™ of ¥19.42. GuruFocus considers GemPharmatech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688046:

  • ROCE %: 9.35%
  • GF Value™: ¥19.42 vs. price of ¥25.77 (32.7% above fair value)
  • GF Score™: 95/100 with 8 warning signs

No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GemPharmatech Co Business Description

Address No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
95GF Score

Get the complete analysis for SHSE:688046

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥25.77
Price
¥19.42
GF Value